StreetInsider.com News Articles

Crescent Biopharma to Present at September Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:

2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.
Morgan Stanley 24^th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 5:35 p.m. ET in New York.

Crescent Biopharma to Present at September Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.
Morgan Stanley 24^th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 5:35 p.m. ET in New York.

TD Cowen Assumes Crescent Biopharma Inc (CBIO) at Buy

Sat, 22 Aug 2026 07:55:23 -0400

TD Cowen analyst Tyl assumes coverage on Crescent Biopharma Inc (NASDAQ: CBIO) with a Buy rating.

For an analyst ratings summary and ratings history on Crescent Biopharma Inc click here. For more ratings news on Crescent Biopharma Inc click here.

Shares of Crescent Biopharma Inc closed at $17.15 yesterday.

Form SCHEDULE 13G/A CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924095.html

Form SCHEDULE 13G/A CRESCENT BIOPHARMA, INC. Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924095.html

Crescent Biopharma Announces Grants of Inducement Awards

Mon, 03 Aug 2026 07:30:00 -0400

WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 19,425 shares of the Company’s ordinary shares to one non-executive employee as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on July 31, 2026 and were

Crescent Biopharma Announces Grants of Inducement Awards

Mon, 03 Aug 2026 07:30:00 -0400

Form EFFECT CRESCENT BIOPHARMA, INC.

Mon, 03 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260803/26853222.html

Form EFFECT CRESCENT BIOPHARMA, INC.

Mon, 03 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260803/26853222.html

H.C. Wainwright Reiterates Neutral Rating on Crescent Biopharma Inc (CBIO)

Fri, 31 Jul 2026 06:47:01 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating on Crescent Biopharma Inc (NASDAQ: CBIO).

The analyst commented: "Consistent with our prior warning, Merck’s briefly-disclosed Phase 2 of MK-2010 + sac-TMT creates headwinds for CR-001. A now-removed Merck & Co. (MRK; not rated) trial listing showed MK-2010-003, an open-label Phase 2 of its PD-1 x VEGF bispecific with sac-TMT in advanced solid tumors, providing the first concrete evidence that Merck is preparing the internally controlled combination that we viewed as the key limitation to the commercial relevance of CR-001 + sac-TMT. Crescent’s 206-patient China NSCLC Phase 2 is underway and

Form POS AM CRESCENT BIOPHARMA, INC.

Thu, 30 Jul 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260730/26840507.html

Form POS AM CRESCENT BIOPHARMA, INC.

Thu, 30 Jul 2026 09:37:00 -0400

si-local-file:///var/storage/secattach/20260730/26840507.html

Form 424B3 CRESCENT BIOPHARMA, INC.

Thu, 30 Jul 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260730/26840486.html

Form 424B3 CRESCENT BIOPHARMA, INC.

Thu, 30 Jul 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260730/26840486.html

Form 10-Q CRESCENT BIOPHARMA, INC. For: Jun 30

Thu, 30 Jul 2026 09:25:00 -0400

si-local-file:///var/storage/secattach/20260730/26840403.html

Form 10-Q CRESCENT BIOPHARMA, INC. For: Jun 30

Thu, 30 Jul 2026 09:25:00 -0400

si-local-file:///var/storage/secattach/20260730/26840403.html

Form 8-K CRESCENT BIOPHARMA, INC. For: Jul 30

Thu, 30 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260730/26838882.html

Form 8-K CRESCENT BIOPHARMA, INC. For: Jul 30

Thu, 30 Jul 2026 07:36:00 -0400

si-local-file:///var/storage/secattach/20260730/26838882.html

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 30 Jul 2026 07:35:00 -0400

Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients

CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China

Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second half of 2026

Multiple key clinical data readouts across the portfolio anticipated beginning in Q1 2027

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 30 Jul 2026 07:35:00 -0400

Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients

CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China

Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second half of 2026

Multiple key clinical data readouts across the portfolio anticipated beginning in Q1 2027

Crescent Biopharma Announces Grants of Inducement Awards

Thu, 23 Jul 2026 16:15:00 -0400

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 52,500 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on July 22, 2026 and were

Crescent Biopharma Announces Grants of Inducement Awards

Thu, 23 Jul 2026 16:15:00 -0400

Form 4 CRESCENT BIOPHARMA, INC. For: Jul 16 Filed by: Kiselak Tomas

Mon, 20 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260720/26790561.html

Form 4 CRESCENT BIOPHARMA, INC. For: Jul 16 Filed by: Kiselak Tomas

Mon, 20 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260720/26790561.html

Form SCHEDULE 13D/A CRESCENT BIOPHARMA, INC. Filed by: Fairmount Funds Management LLC

Mon, 20 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260720/26790562.html